Strategically influence nonclinical drug safety considerations for Immunology programs by providing drug development mentorship and partnering with Compound Leaders on time-critical matters, including nonclinical program design and toxicology study design, weight-of-evidence risk assessments, science-based waiver strategies, and integrated safety development plans that support clinical trials, global registration, and timely resolution of nonclinical development issues. Provide scientific and strategic oversight for Immunology candidates through close collaboration with Program Coordinators, Discovery Preclinical Leaders, Compound Leaders, and scientists across NDS and/or Preclinical Development, while ensuring strong partnership with key Research and Development Division functions, including Discovery, chemistry, regulatory affairs, translational medicine, clinical development, and CMC.